2 ms·
There is some research currently on low doses of naloxone as a treatment for long Covid/CFS/ME. Would naloxone have anything to do with this protein, or is it
by AnimalMuppet 3y ago
There is some research currently on low doses of naloxone as a treatment for long Covid/CFS/ME. Would naloxone have anything to do with this protein, or is it an unrelated approach?
- PaulKeeble 3y agoWe think it just reduces some of the brain inflammation and thus alleviates some of the symptoms. Its also a treatment sufferers become tolerant to and it stops working. Its also very hard to dose right and requires constant adjustments and its not without side effects that often make it not worthwhile and for some people it never works. It should be authorised as a treatment for ME/CFS and Long Covid in the short term alongside Ablify as sufferers should get to try these and see if they work but they are both very far from a good treatment and do nothing for the core parts of the condition.
- nradov 3y agoThere's no process to "authorize" an existing approved prescription drug as a treatment for ME/CFS and Long COVID. Doctors can already prescribe those drugs off label if they wish (although the patient might have trouble getting insurance coverage for those claims depending on their policy). In order to make them on-label treatments then the drug company or some other party will have to conduct a large-scale clinical trial and go through the FDA regulatory process to prove that it is safe and effective. This is expensive, but drug companies do such studies all the time in order to increase revenue and extend patent protections.
- GordonS 3y agoIt depends on the country. In the UK for example, medications are indeed licensed to treat certain conditions. Specialist doctors are able to prescribe off-label regardless, but most are reticent to do so.
- InSteady 3y agoI could be wrong, but I believe naloxone isn't really orally bioavailable. Most of the very limited research focuses on low dose naltrexone (LDN) instead, naltrexone being another opioid receptor antagonist with paradoxical properties, namely analgesic and anti-inflammatory properties, at low dosages. There could be a link here, although it is tenuous and purely lay speculation. ER stress is discussed in the article: >Both S1 and the people with ME/CFS had biochemical signatures of ER stress in their muscles, and treating S1’s cells in a dish with a drug that blocks ER stress lowered WASF3 levels and restored mitochondrial function. On the flipside, using toxins to artificially induce ER stress in cultured cells or in mice caused a rise in WASF3 levels, Hwang says. LDN has been found to be quite effective in alleviating ER stress specifically in the epithelial barrier in IBD [0], rather than the ER stress - WASF3 levels being investigated in muscle cells in the above article. Certainly worth investigating. And, as noted in the article, the WASF3 angle is merely one potential pathway of the disorder. [0] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5845217/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5845217/ >Low dose Naltrexone induced clinical improvement in 74.5%, and remission in 25.5% of patients. Naltrexone improved wound healing and reduced ER stress induced by Tunicamycin, lipopolysaccharide or bacteria in epithelial barriers.
- ypeterholmes 3y agoThere was also a study out of Yale showing effectiveness with a combination of guanfacine and N-acetylcysteine (NAC), an anti-oxidant also used for the treatment of TBI. https://medicine.yale.edu/news-article/potential-new-treatment-for-brain-fog-in-long-covid-patients/ https://medicine.yale.edu/news-article/potential-new-treatme...